Abstract:Dominant mutations in the calcium-permeable ion channel TRPV4 (transient receptor potential vanilloid 4) cause diverse and largely distinct channelopathies, including inherited forms of neuromuscular disease, skeletal dysplasias, and arthropathy. Pathogenic TRPV4 mutations cause gain of ion channel function and toxicity that can be rescued by small molecule TRPV4 antagonists in cellular and animal models, suggesting that TRPV4 antagonism could be therapeutic for patients. Numerous variants in TRPV4 have been detected with targeted and whole exome/genome sequencing, but for the vast majority, their pathogenicity remains unclear. Here, we used a combination of clinical information and experimental structure-function analyses to evaluate 30 TRPV4 variants across various functional protein domains. We report clinical features of seven patients with TRPV4 variants of unknown significance and provide extensive functional characterization of these and an additional 17 variants, including structural position, ion channel function, subcellular localization, expression level, cytotoxicity, and protein-protein interactions. We find that gain-of-function mutations within the TRPV4 intracellular ankyrin repeat domain target charged amino acid residues important for RhoA interaction, whereas ankyrin repeat domain residues outside of the RhoA interface have normal or reduced ion channel activity. We further identify a cluster of gain-of-function variants within the intracellular intrinsically disordered region that may cause toxicity via altered interactions with membrane lipids. In contrast, assessed variants in the transmembrane domain and other regions of the intrinsically disordered region do not cause gain of function and are likely benign. Clinical features associated with gain of function and cytotoxicity include congenital onset of disease, vocal cord weakness, and motor predominant disease, whereas patients with likely benign variants often demonstrated late-onset and sensory-predominant disease. These results provide a framework for assessing additional TRPV4 variants with respect to likely pathogenicity, which will yield critical information to inform patient selection for future clinical trials for TRPV4 channelopathies.

Reviewing critical TRPM2 variants through a structure-function lens

A TRPV4 Channel C-terminal Folding Recognition Domain Critical for Trafficking and Function.

The identification of the key residues E829 and R845 involved in transient receptor potential melastatin 2 channel gating

Combined clinical, structural, and cellular studies discriminate pathogenic and benign TRPV4 variants

Exploring therapeutic potential: Targeting TRPM7 in neurodegenerative diseases

TRPM7 Functions in Non-Neuronal and Neuronal Systems: Perspectives on Its Role in the Adult Brain

TRPM7 in neurodevelopment and therapeutic prospects for neurodegenerative disease

Structure-Function Relationship of TRPM2: Recent Advances, Contradictions, and Open Questions

TRPM channels in health and disease

From oxidative stress to metabolic dysfunction: The role of TRPM2

Transient receptor proteins illuminated: current views on TRPs and disease

TRPM2: a calcium influx pathway regulated by oxidative stress and the novel second messenger ADP-ribose

Research progress on transient receptor potential melastatin 2 channel in nervous system diseases.

Recent advances on the structure and the function relationships of the TRPV4 ion channel

Medicinal Chemistry Perspective Of Trpm2 Channel Inhibitors: Where We Are And Where We Might Be Heading?

Bidirectional regulation mechanism of TRPM2 channel: role in oxidative stress, inflammation and ischemia-reperfusion injury

Calcium selective channel TRPV6: Structure, function, and implications in health and disease

Role of the chanzyme TRPM7 in the nervous system in health and disease

Structure-function analyses of human TRPV6 ancestral and derived haplotypes

TRPM8 Channels: A Review of Distribution and Clinical Role

Aberrant Deactivation-Induced Gain of Function in TRPM4 Mutant Is Associated with Human Cardiac Conduction Block.